Sigyn Therapeutics, Inc. (SIGY) stock
SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $48.16KP/E –Yield –
Sigyn Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Sigyn Therapeutics's net income for the twelve months ending Sep 30, 2025 was -$3.22M. For fiscal 2024 it was -$3.34M. The highest annual figure on record is -$387.54K in fiscal 2014.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$3.34M | – |
| FY2023 | Dec 31, 2023 | -$4.15M | – |
| FY2022 | Dec 31, 2022 | -$2.93M | – |
| FY2021 | Dec 31, 2021 | -$3.00M | – |
| FY2020 | Dec 31, 2020 | -$1.26M | – |
| FY2019 | Dec 31, 2019 | -$3.07M | – |
| FY2018 | Dec 31, 2018 | -$2.62M | – |
| FY2017 | Dec 31, 2017 | -$4.25M | – |
| FY2015 | Dec 31, 2015 | -$2.69M | – |
| FY2014 | Dec 31, 2014 | -$387.54K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -$578.50K | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$668.56K | – |
| Q4 FY2024 | Dec 31, 2024 | -$522.82K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$862.38K | – |
| Q1 FY2024 | Mar 31, 2024 | -$758.09K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$905.73K | – |
| Q2 FY2023 | Jun 30, 2023 | -$723.12K | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$858.94K | – |
| Q3 FY2022 | Sep 30, 2022 | -$726.51K | – |
| Q2 FY2022 | Jun 30, 2022 | -$666.33K | – |
| Q1 FY2022 | Mar 31, 2022 | -$678.05K | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.23M | – |
| Q3 FY2021 | Sep 30, 2021 | -$665.90K | – |
| Q2 FY2021 | Jun 30, 2021 | -$649.86K | – |
| Q1 FY2021 | Mar 31, 2021 | -$461.68K | – |
| Q4 FY2020 | Dec 31, 2020 | -$452.02K | – |
| Q3 FY2020 | Sep 30, 2020 | -$295.99K | – |
| Q2 FY2020 | Jun 30, 2020 | -$260.40K | – |
| Q1 FY2020 | Mar 31, 2020 | -$251.18K | -565.5% |
| Q4 FY2019 | Dec 31, 2019 | -$2.87M | – |
| Q3 FY2019 | Sep 30, 2019 | -$138.58K | – |
| Q2 FY2019 | Jun 30, 2019 | -$116.82K | – |
| Q1 FY2019 | Mar 31, 2019 | $53.96K | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.22M | – |
| Q3 FY2018 | Sep 30, 2018 | -$355.99K | – |
| Q2 FY2018 | Jun 30, 2018 | -$307.28K | – |
| Q1 FY2018 | Mar 31, 2018 | -$739.39K | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.18M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.50M | – |
| Q2 FY2017 | Jun 30, 2017 | -$967.49K | – |
| Q1 FY2017 | Mar 31, 2017 | -$613.90K | – |
| Q3 FY2016 | Sep 30, 2016 | -$432.52K | – |
| Q2 FY2016 | Jun 30, 2016 | -$885.70K | – |
| Q1 FY2016 | Mar 31, 2016 | -$851.24K | – |
| Q4 FY2015 | Dec 31, 2015 | -$1.25M | – |
See a number that looks wrong?